Genomics is likely one of the most important long-term investment themes of the next decade, as AI speeds how life's information is read, understood and edited. Picks: Illumina in sequencing; Tempus AI for AI with genomic data; CRISPR Therapeutics and Beam in gene editing; uniQure (high risk, high payoff) and BioMarin (more certain) in gene therapy; Natera and Guardant Health in diagnostics; Twist Bioscience and Thermo Fisher in tools; Vertex and Alnylam in therapeutics. x.com 

Eli Lilly's GLP-1 and metabolic franchise can compound demand and cash flows while rate fears punish leveraged AI stories. It is preferable as a defensive-growth holding into its October 29 earnings over chasing a chip bounce. Continued healthcare volume leadership would support the sleeve; if semiconductors reclaim leadership first, the rotation is already crowded the other way. x.com  x.com 

Biotech tools stocks such as Charles River and Illumina are in a narrative-driven mania while their fundamentals haven't really moved. Charles River is ripping after reaffirming guidance for negative revenue growth this year. Illumina hasn't grown in five years, yet trades at over 50x earnings and 35x EV/EBITDA, with merely fine margins. Five straight years of easier comparisons are being sold as a coiled spring. x.com  x.com  x.com 

Biotech, including Thermo Fisher, Eli Lilly, Intellia, CRISPR, Illumina and NeoGenomics, stands to gain as AI-trade capital rotates out of infrastructure, since healthcare is the largest market AI has yet to disrupt. AI hardware is worth about $14 trillion versus $1.4 trillion for biotech, so a 2.5% rotation could, at 5x inelasticity, put $1.75 trillion of pressure on biotech. Capital isn't leaving the AI trade; the equal-weighted S&P 500 is at all-time highs. x.com  x.com 

Boston Scientific and Abbott are cheaper than their history but unlikely to compound at 20% over the next five years. The medical-device selloff looks like a clear overreaction, but Intuitive Surgical is worth paying up for even after a 30% drawdown, and TransMedics and PROCEPT BioRobotics have a real shot at about 30% annual returns over five years on 20%-plus revenue growth, operating leverage and possible multiple expansion. Favoring growth over cheaper names means more risk but more upside. … Show more

High-quality healthcare companies such as Thermo Fisher, Boston Scientific, Novo Nordisk and Abbott now trade at washed-out multiples, which may make the space one of the cheapest pockets of the market on a quality-adjusted basis while SaaS draws the attention. x.com 

Genomics stocks appear to be benefiting from AI, with the ARK Genomic Revolution ETF clearly outpacing broader biotech. x.com 

The biotech and genomics boom is best owned broadly, because single biotech stocks are binary bets on trial results no analyst can handicap. One failed readout can halve a stock, as Novo Nordisk's lost market value on disappointing data showed. Owning blue-chip biotech and high-beta genomics as diversified baskets captures the funding rebound, the AI drug-discovery tailwind and the re-rating after years of deep bear market and a decisive breakout, without the single-molecule lottery. x.com  x.com  … Show more

GE HealthCare's chart looks constructive and September call options carry low implied volatility. Medical device and diagnostics companies may also see a rotation driven by physical AI. x.com  x.com 

Biotech is the next AI trade after compute and memory as the market shifts to the application layer, and the ARK Genomic Revolution ETF could top $100. Biotech runs on data, pattern recognition, R&D and precise manufacturing, all things AI excels at, helping firms like Twist, Tempus and CRISPR make drugs faster and reach profit sooner. The Trump administration is also opening the door to innovation and M&A. Winners are hard to pick, so a basket is easiest; expect volatility. x.com  x.com  x.com  … Show more